Drug-Eluting Stents in Preclinical Studies: Recommended Evaluation From a Consensus Group

The arrival of drug-eluting stents raises important questions about preclinical evaluation of devices and the optimal means of predicting clinical safety and efficacy. The Interventional, Regulatory, Commercial, and Scientific communities have all asked for assistance in defining criteria for device evaluation. This document is an integrated view of requirements for evaluating drug-eluting stents in preclinical models. The suggested requirements encompass study design, experimental performance, and histopathologic evaluations, emphasizing safety and efficacy at multiple points in time. This is a consensus document assembled by clinical, academic, and industrial investigators engaged in preclinical interventional device evaluation. Suggested requirements might well serve as a standard but do not prescribe a single manner in which all devices should be evaluated. They instead motivate such an evaluation and describe how examinations might be performed. It is understood that methods will change and knowledge will evolve, in particular as corroboration is established with clinical data. The dynamic nature of this document allows for future modifications and additions. A drug-eluting stent presents or releases single or multiple bioactive agents into the blood stream. The drug can deposit in and/or affect blood vessels, cells, plaque, or tissues either adjacent to the stent or at a distance. Systemic drug concentrations may be avoided or desirable. It is assumed that drugs undergoing preclinical evaluation will have sound theoretical and practical reasons for biological success, and that the preclinical studies will help answer the magnitude and safety of effect when presented with or from the stent. It is likely that substantial empirical data already exists documenting the effects of these drugs on isolated cells in culture and even in vivo after systemic administration. Some drugs may already be in clinical use. Drug can be embedded and released from within (“matrix-type”) or surrounded by and released through (“reservoir-type”) polymer materials that coat …

[1]  Elazer R. Edelman,et al.  Gold-Coated NIR Stents in Porcine Coronary Arteries , 2001, Circulation.

[2]  E. Edelman,et al.  Local drug delivery: an emerging approach in the treatment of restenosis , 2000, Vascular medicine.

[3]  R. Virmani,et al.  Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent , 2001, Circulation.

[4]  E. Edelman,et al.  Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. , 2000, Journal of the American College of Cardiology.

[5]  R. Schwartz The vessel wall reaction in restenosis. , 1997, Seminars in interventional cardiology : SIIC.

[6]  Renu Virmani,et al.  Experimental evaluation of a short transitional edge protection balloon for intracoronary stent deployment , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[7]  N. Uren,et al.  Intracoronary stents , 1996, BMJ.

[8]  Schwartz Characteristics of an Ideal Stent Based Upon Restenosis Pathology. , 1996, The Journal of invasive cardiology.

[9]  D. Baim,et al.  Short‐ and long‐term histopathologic evaluation of stenting using a self‐expanding nitinol stent in pig carotid and iliac arteries , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[10]  W. Edwards,et al.  Polymeric stenting in the porcine coronary artery model: differential outcome of exogenous fibrin sleeves versus polyurethane-coated stents. , 1994, Journal of the American College of Cardiology.

[11]  R E Vlietstra,et al.  Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. , 1992, Journal of the American College of Cardiology.

[12]  R. Virmani,et al.  Pathology of acute and chronic coronary stenting in humans. , 1999, Circulation.

[13]  A. Yeung,et al.  ”Metaling” with new stent designs , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[14]  E. Edelman,et al.  Pathobiologic responses to stenting. , 1998, The American journal of cardiology.

[15]  R. Schwartz,et al.  Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. , 1998, The American journal of cardiology.

[16]  U. Sigwart,et al.  Self expanding stents for the management of aorto-ostial stenoses in saphenous vein bypass grafts. , 1994, British heart journal.

[17]  R. Virmani,et al.  A comparison of four stent designs on arterial injury, cellular proliferation, neointima formation, and arterial dimensions in an experimental porcine model , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[18]  F. Happey Synthetic Polymers , 1955, Nature.

[19]  M. S. Williams,et al.  Stent and artery geometry determine intimal thickening independent of arterial injury. , 2000, Circulation.

[20]  R. Virmani,et al.  Pathology of in-stent restenosis. , 1999, Current opinion in lipidology.

[21]  A. Bayés‐Genís,et al.  Pressure rinsing of coronary stents immediately before implantation reduces inflammation and neointimal hyperplasia. , 2001, Journal of the American College of Cardiology.

[22]  R E Vlietstra,et al.  Percutaneous Polymeric Stents in Porcine Coronary Arteries: Initial Experience With Polyethylene Terephthalate Stents , 1992, Circulation.

[23]  P. Tsao,et al.  Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model , 2001, Circulation.

[24]  E. Edelman,et al.  Physiological Transport Forces Govern Drug Distribution for Stent-Based Delivery , 2001, Circulation.

[25]  E. Topol,et al.  Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. , 1996, Circulation.

[26]  A. Carter,et al.  Rapamycin eluting stent: the onset of a new era in interventional cardiology , 2002, Heart.